Načítá se...
GnRHa/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty
BACKGROUND: Gonadotropin-releasing hormone agonist (GnRHa) is the gold standard in the treatment of Central Precocious Puberty (CPP) with progressive puberty and accelerative growth. However, GnRHa treatment is reported to result in growth deceleration and prevents growth plate development which lea...
Uloženo v:
| Vydáno v: | Front Endocrinol (Lausanne) |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8221533/ https://ncbi.nlm.nih.gov/pubmed/34177807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.678797 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|